Compare Inovio Pharmaceuticals Inc (INO) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Thomson Reuters Corp — how do they compare? Inovio Pharmaceuticals Inc trades at $0.78 (market cap $76.09M), while Thomson Reuters Corp trades at $104.52 (market cap $45.08B). The key difference: Thomson Reuters Corp is far larger — about 592.5× Inovio Pharmaceuticals Inc's market cap, and Thomson Reuters Corp pays a 2.51% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | TRI | |
|---|---|---|
Market Cap | $76.09M | $45.08B |
Sector | Health | Industrials |
52-Week High | $2.87 | $178.77 |
52-Week Low | $0.66 | $76.55 |
Enterprise Value | $47.10M | $47.69B |
Dividend Yield | — | 2.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.668, down 0.86% with bearish technical signals despite recent earnings beats. The company shows minimal revenue of $65,340 against substantial losses, with negative margins and cash flow challenges. Key catalyst is the FDA's October 2026 decision on INO-3107, while recent $20 million offering aims to fund operations.
High-risk biotech play with binary FDA outcome driving valuation. Analyst consensus is bullish (53% buy) with $3.25 price target, but fundamental weaknesses and litigation risks require caution. Success of INO-3107 is critical for turnaround, with current cash funding operations into early 2027.
Thomson Reuters (TRI) trades at $101.83, up 1.68% today, near the consensus price target of $102.33. The stock shows strong technical momentum with bullish moving averages and support at $99. Fundamentally, TRI delivered Q2 2026 earnings beat ($0.99 vs. $0.96 expected) with 8% organic revenue growth, while maintaining robust profitability margins (21.22% net income margin). Recent news highlights AI-driven product momentum and raised full-year revenue guidance.
Outlook remains positive with analyst consensus favoring Buy (51.85%) and 29.8% upside potential to high target of $124. Key risks include execution on AI transition and competitive pressures in legal/tax software markets. The company's recurring revenue model (82% of total) and dividend payments provide stability amid growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
